Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

• Main Authors: James T. Peterson (Author), Helen L. Stacey (Author), John E. MacNair (Author), Jianing Li (Author), Jonathan S. Hartzel (Author), Tina M. Sterling (Author), Patrice Benner (Author), Gretchen M. Tamms (Author), Luwy K. Musey (Author)
• Format: Book
• Published: Taylor & Francis Group, 2019-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Pneumococcal disease remains a public health priority in adults. Previous studies have suggested that administration of pneumococcal polysaccharide vaccine or pneumococcal conjugate vaccine within three years following receipt of PPV23 was associated with increased reactogenicity and red...